Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 8/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | IDE | P14735 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715742 | 0.83 | APP (0.56) | SERPINE1ENPP2AKR1C3PTGS2 | |
| SCHEMBL1577733 | 0.82 | ENPP2 (0.52) | SERPINE1ENPP2ALDH1A1LMNAGAA | |
| SCHEMBL10518952 | 0.82 | SMN1; SMN2 (0.55) | SERPINE1ENPP2ALDH1A1LMNAPTGS1 | |
| SCHEMBL26936872 | 0.82 | ENPP2 (0.52) | SERPINE1ENPP2ALDH1A1LMNAPTGS1 | |
| SCHEMBL28018960 | 0.82 | ENPP2 (0.52) | SERPINE1ENPP2AKR1C3ALDH1A1HSD17B10 | |
| SCHEMBL1368815 | 0.80 | ENPP2 (0.50) | SERPINE1ENPP2AKR1C3ALDH1A1HSD17B10 | |
| SCHEMBL634380 | 0.80 | GAA (0.70) | SERPINE1ENPP2ALDH1A1HSD17B10LMNA | |
| SCHEMBL6932811 | 0.80 | G6PD (0.58) | SERPINE1ENPP2ALDH1A1HSD17B10LMNA | |
| SCHEMBL1577323 | 0.80 | ENPP2 (0.50) | SERPINE1ENPP2AKR1C3LMNAG6PD | |
| SCHEMBL15036811 | 0.80 | ENPP2 (0.50) | SERPINE1ENPP2AKR1C3ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040094198-A1 | n-type Metal oxide semiconductor spectrally sensitized with a cationic spectral sensitizer | AGFA-GEVAERT (BE) | 2004-05-20 | — | — | US | claimed |
| US-5438052-A | Cephalosporin derivatives | HOFFMANN-LA ROCHE INC. (US) | 1995-08-01 | — | — | US | claimed |
| WO-2023072106-A1 | BINDER AND LITHIUM-ION BATTERY COMPRISING SAME | 珠海冠宇电池股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | EASTERN MICHIGAN UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-9718760-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-11-05 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2491785-A1 | Method and compositions for treating HIV infections | Purdue Research Foundation (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20040094198-A1 | n-type Metal oxide semiconductor spectrally sensitized with a cationic spectral sensitizer | AGFA-GEVAERT (BE) | 2004-05-20 | — | — | US | disclosed |
| WO-2004025674-A1 | N-TYPE METAL OXIDE SEMICONDUCTOR SPECTRALLY SENSITIZED WITH A CATIONIC SPECTRAL SENSITIZER | AGFA-GEVAERT (BE) | 2004-03-25 | — | — | WO | disclosed |
| US-6693062-B2 | LIGHT INSENSITIVE ORGANIC SILVER SALTS, REDUCING AGENTS AND 1,2-DIHYDROXYBENZENE DERIVATIVE | AGFA-GEVAERT (BE) | 2004-02-17 | — | — | US | disclosed |
| US-20030064891-A1 | Thermographic recording material with improved image tone | AGFA-GEVAERT (BE) | 2003-04-03 | — | — | US | disclosed |
| EP-1245403-A1 | Thermographic recording material with improved image tone. | Agfa-Gevaert (BE) | 2002-10-02 | — | — | EP | disclosed |
| US-5438052-A | Cephalosporin derivatives | HOFFMANN-LA ROCHE INC. (US) | 1995-08-01 | — | — | US | disclosed |
| EP-0544166-A2 | Cephalosporinderivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| US-4558129-A | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade | SYNTEX (U.S.A.) INC. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | SERPINE1 1/4885ENPP2 132/4885AKR1C3 979/4885 |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | SERPINE1 1/4885ENPP2 132/4885AKR1C3 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.